Policy
Policy & Regulation
How different regulators — the FDA, EMA, and NMPA — approve, classify, and oversee GLP-1 medications, and what that means for prescribing and access.
How the FDA's Compounding Exemption Law Actually Works
Federal law allows pharmacy compounding under specific exemptions from standard drug approval requirements. Here's the legal structure behind that exemption.
6 min read
State-by-State Telehealth Prescribing Rules for GLP-1 Drugs
Telemedicine practice standards are set at the state level in the U.S., which means the rules governing a GLP-1 telehealth prescription can change at a state line.
6 min read
Canada: Health Canada Approval and Provincial Coverage Differences
Health Canada approves GLP-1 drugs nationally, but public drug coverage is administered provincially, creating access differences similar to the EU's member-state model.
5 min read
United Kingdom: MHRA Approval and NHS Access Rules
Post-Brexit, the UK's MHRA runs its own approval process separate from the EMA, and NHS access to GLP-1 drugs runs through NICE cost-effectiveness review.
6 min read
United States: FDA Approval Pathway and Prescribing Rules for GLP-1 Drugs
How GLP-1 medications move through FDA approval, what prescription-only status means in practice, and where telehealth prescribing fits in.
6 min read
Off-Label Prescribing: What's Legal, and What Insurance Won't Touch
Off-label prescribing is legal in the U.S. and common in medicine generally. Here's the legal basis for it, and why it doesn't guarantee insurance coverage.
5 min read
European Union: EMA Approval and Member-State Access Differences
The EMA approves GLP-1 drugs at the EU level, but pricing, reimbursement, and day-to-day access still vary significantly by member state.
5 min read
China: NMPA Approval Status and the Domestic GLP-1 Market
China's National Medical Products Administration has approved semaglutide for diabetes and, more recently, weight management, alongside a growing field of domestic GLP-1 candidates.
6 min read
Direct-to-Consumer Drug Advertising Rules and GLP-1 Marketing
The U.S. is one of the only countries that allows direct-to-consumer prescription drug advertising, and GLP-1 drugs have become some of its most visible examples.
5 min read
Medicare Part D Negotiation and GLP-1 Drugs, Explained
Medicare's drug price negotiation authority is new, statutorily limited, and doesn't automatically apply to every high-profile drug. Here's the actual legal structure.
5 min read
Australia: TGA Approval and PBS Subsidy Rules
Australia's Therapeutic Goods Administration approves GLP-1 drugs, but Pharmaceutical Benefits Scheme subsidy is a separate, additional decision that determines affordability.
5 min read
State Insurance Mandates for Obesity Treatment Coverage
A small number of U.S. states have passed laws requiring certain insurance plans to cover obesity treatment, including GLP-1 drugs. Here's how those mandates work.
6 min read
Japan: PMDA Approval and National Health Insurance Coverage
Japan's Pharmaceuticals and Medical Devices Agency reviews GLP-1 drugs under its own process, with coverage tied to the country's universal National Health Insurance system.
5 min read
How the FDA Actually Declares and Resolves a Drug Shortage
A drug shortage designation follows a specific legal and evidentiary process, not a simple observation that a pharmacy is out of stock.
5 min read
India: CDSCO Status and the Domestic Generics Question
India's patent and regulatory landscape has made it an early test case for lower-cost GLP-1 competition, subject to its own approval and patent rules.
6 min read
Brazil: ANVISA Approval and Public Health System Access
Brazil's ANVISA regulates GLP-1 drugs nationally, with access shaped by both the public SUS health system and a large private insurance market.
5 min read
Prior Authorization: How Insurers Gatekeep GLP-1 Coverage
Prior authorization is the main tool insurers use to manage GLP-1 drug costs. Here's how the process typically works and what commonly triggers a denial.
6 min read
South Korea: MFDS Approval Status for GLP-1 Drugs
South Korea's Ministry of Food and Drug Safety reviews GLP-1 drugs under its own national process, alongside a growing domestic biopharmaceutical sector.
4 min read
Pharmacy Compounding Oversight: State Boards vs. Federal FDA Roles
Compounding pharmacies are regulated by both state pharmacy boards and the FDA, with overlapping but distinct authority. Here's how the split works.
6 min read
Mexico: COFEPRIS Approval and Cross-Border Purchasing Questions
Mexico's COFEPRIS regulates GLP-1 drugs domestically, and the country has become a common topic in discussions of cross-border purchasing by U.S. patients.
5 min read
Customs and Personal-Import Rules for Prescription Drugs
Bringing prescription drugs into the U.S. from abroad, including GLP-1 drugs, is subject to specific and often misunderstood federal rules.
5 min read
The Biosimilar Approval Pathway for GLP-1 Drugs, Explained
Because semaglutide and tirzepatide are peptides, follow-on competitors go through the biosimilar pathway, not the small-molecule generic pathway. Here's the difference.
6 min read
The FDA's Legal Powers to Combat Counterfeit Drugs
The FDA has specific statutory tools for counterfeit drug enforcement, working alongside customs authorities and, in serious cases, criminal law enforcement.
5 min read
What Companies Are Legally Required to Disclose About GLP-1 Clinical Trials
U.S. law requires registration and results reporting for many clinical trials on ClinicalTrials.gov. Here's what that requirement actually covers.
5 min read
Patent and Regulatory Exclusivity Periods for GLP-1 Drugs, Explained
Patents and FDA regulatory exclusivity are two separate legal protections that both affect when competition can enter the GLP-1 market.
6 min read
State Drug Importation Programs: How They Actually Work
Several states have pursued federally authorized programs to import lower-cost drugs from Canada. Here's the legal mechanism behind those efforts.
5 min read
Employer Wellness Program Rules and GLP-1 Incentive Structures
Employers offering GLP-1 coverage tied to wellness program participation must navigate federal rules governing health-contingent incentives.
6 min read
FTC Scrutiny of Telehealth Weight-Loss Marketing Claims
The Federal Trade Commission has authority over deceptive advertising, and telehealth weight-loss marketing has drawn increasing attention under that authority.
5 min read
The WHO's Position on GLP-1 Drugs in Global Obesity Policy
The World Health Organization has weighed in on GLP-1 drugs' role in global obesity management, alongside concerns about access equity between wealthy and lower-income countries.
6 min read
What an 'Essential Health Benefit' Designation Would Mean for GLP-1 Coverage
Essential health benefit categories shape what ACA-compliant plans must cover. Here's how that framework interacts with anti-obesity medication coverage debates.
6 min read